These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 38616729)
1. Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1. Yang S; Yu Y; Jian F; Yisimayi A; Song W; Liu J; Wang P; Xu Y; Wang J; Niu X; Yu L; Wang Y; Shao F; Jin R; Wang Y; Cao Y Emerg Microbes Infect; 2024 Dec; 13(1):2343909. PubMed ID: 38616729 [TBL] [Abstract][Full Text] [Related]
2. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion. Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890 [TBL] [Abstract][Full Text] [Related]
3. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Cao Y; Jian F; Wang J; Yu Y; Song W; Yisimayi A; Wang J; An R; Chen X; Zhang N; Wang Y; Wang P; Zhao L; Sun H; Yu L; Yang S; Niu X; Xiao T; Gu Q; Shao F; Hao X; Xu Y; Jin R; Shen Z; Wang Y; Xie XS Nature; 2023 Feb; 614(7948):521-529. PubMed ID: 36535326 [TBL] [Abstract][Full Text] [Related]
4. Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants. Yang H; Guo H; Wang A; Cao L; Fan Q; Jiang J; Wang M; Lin L; Ge X; Wang H; Zhang R; Liao M; Yan R; Ju B; Zhang Z Nat Commun; 2024 Sep; 15(1):7715. PubMed ID: 39231977 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1. Wang Q; Guo Y; Schwanz LT; Mellis IA; Sun Y; Qu Y; Urtecho G; Valdez R; Stoneman E; Gordon A; Wang HH; Ho DD; Liu L Emerg Microbes Infect; 2024 Dec; 13(1):2359004. PubMed ID: 38779718 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620 [TBL] [Abstract][Full Text] [Related]
7. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies. He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739 [TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster. Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825 [TBL] [Abstract][Full Text] [Related]
9. Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants. Li L; Shi K; Gu Y; Xu Z; Shu C; Li D; Sun J; Cong M; Li X; Zhao X; Yu G; Hu S; Tan H; Qi J; Ma X; Liu K; Gao GF Structure; 2024 Aug; 32(8):1055-1067.e6. PubMed ID: 39013463 [TBL] [Abstract][Full Text] [Related]
10. Glycan masking of NTD loops with a chimeric RBD of the spike protein as a vaccine design strategy against emerging SARS-CoV-2 Omicron variants. Hung HC; Tan BF; Lin WS; Wu SC J Med Virol; 2024 Sep; 96(9):e29893. PubMed ID: 39192804 [TBL] [Abstract][Full Text] [Related]
11. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines. Lustig Y; Barda N; Weiss-Ottolenghi Y; Indenbaum V; Margalit I; Asraf K; Doolman R; Chalkias S; Das R; Elfatarany G; Harats D; Kreiss Y; Regev-Yochay G Vaccine; 2024 Sep; 42(22):126010. PubMed ID: 38806352 [TBL] [Abstract][Full Text] [Related]
12. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity. Liu C; Zhou D; Dijokaite-Guraliuc A; Supasa P; Duyvesteyn HME; Ginn HM; Selvaraj M; Mentzer AJ; Das R; de Silva TI; Ritter TG; Plowright M; Newman TAH; Stafford L; Kronsteiner B; Temperton N; Lui Y; Fellermeyer M; Goulder P; Klenerman P; Dunachie SJ; Barton MI; Kutuzov MA; Dushek O; ; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR Cell Rep Med; 2024 May; 5(5):101553. PubMed ID: 38723626 [TBL] [Abstract][Full Text] [Related]
13. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Wang Q; Guo Y; Iketani S; Nair MS; Li Z; Mohri H; Wang M; Yu J; Bowen AD; Chang JY; Shah JG; Nguyen N; Chen Z; Meyers K; Yin MT; Sobieszczyk ME; Sheng Z; Huang Y; Liu L; Ho DD Nature; 2022 Aug; 608(7923):603-608. PubMed ID: 35790190 [TBL] [Abstract][Full Text] [Related]
14. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
15. Protective Non-neutralizing anti-N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence. Izadi A; Godzwon M; Söderlund Strand A; Schmidt T; Kumlien Georén S; Drosten C; Ohlin M; Nordenfelt P J Immunol; 2024 Sep; 213(5):678-689. PubMed ID: 39018495 [TBL] [Abstract][Full Text] [Related]
16. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Wang Q; Mellis IA; Ho J; Bowen A; Kowalski-Dobson T; Valdez R; Katsamba PS; Wu M; Lee C; Shapiro L; Gordon A; Guo Y; Ho DD; Liu L Emerg Microbes Infect; 2024 Dec; 13(1):2402880. PubMed ID: 39259045 [TBL] [Abstract][Full Text] [Related]
17. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194 [TBL] [Abstract][Full Text] [Related]
18. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera. Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A Virology; 2024 Jul; 595():110067. PubMed ID: 38653156 [TBL] [Abstract][Full Text] [Related]
19. FLip mutations (L455F + F456L) in newly emerging VOI, JN.1: Its antibody and immune escape. Chakraborty C; Bhattacharya M Int Immunopharmacol; 2024 May; 133():112146. PubMed ID: 38677090 [TBL] [Abstract][Full Text] [Related]
20. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cao Y; Yisimayi A; Bai Y; Huang W; Li X; Zhang Z; Yuan T; An R; Wang J; Xiao T; Du S; Ma W; Song L; Li Y; Li X; Song W; Wu J; Liu S; Li X; Zhang Y; Su B; Guo X; Wei Y; Gao C; Zhang N; Zhang Y; Dou Y; Xu X; Shi R; Lu B; Jin R; Ma Y; Qin C; Wang Y; Feng Y; Xiao J; Xie XS Cell Res; 2021 Jul; 31(7):732-741. PubMed ID: 34021265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]